Eleventh session of the Joint Action Forum (JAF), Paris, France,6-9 December 2005 : final Communiqué

?t I AFRICAN PROGRAMME FOR ONCHOCERCIASIS CONTROL (APOC) Eleventh Session of the Joint Action Forum (JAF) Paris, France,6-9 December 2005 Final Communiqu6 At the invitation of the Government of France, the Eleventh Session of the Joint Action Forum (JAF) was held at the Kleber International Conference Center in Paris, France from 6 to 9 December 2005. The meeting was attended by donor countries and institutions, participating countries, Merck and Co. Inc, Non Governmental Development Organizations (NGDOs), the Technical Consultative Committee (TCC) of APOC, the West African Health Organization (WAHO), the External Evaluation Team of APOC, the Mid-Term Review team of the Special Intervention Zones (SIZ) of the former OCP, the onchocerciasis national coordinators of some ex- OCP countries, WHO secretariat and APOC Management. A complete list of participants is attached as Annex 1. 2. In their opening statements, His Excellency, Prof. Emile Bongeli Yeikolo Ya Ato, Honourable Minister of Health, DRC and Chair of JAFI0, and Dr Catherine Le Galds-Camus, representing the Director-General of WHO, outlined the activities of APOC over the last twelve months. They expressed their gratitude to the donor community for its continued support to onchocerciasis control efforts despite the competing demands from other prominent diseases such as HIV/AIDS, Malaria, Tuberculosis and Avian flu. Both speakers listed the impressive achievements of APOC, highlighted the challenges facing the Programme and stressed the need to extend the operations of APOC until 2015 in order to complete the implementation of CDTI projects in a sustainable manner. 3. The Forum paid tribute to Dr Azodoga S6kdtdli, former Director of APOC, for his strong leadership of APOC over the last l0 years and wished him a happy retirement. The Forum also congratulated Dr Uche Amazigo on her appointment as new Director of APOC and pledged its full support to her in her daunting responsibilities. 4. Dr Uche Amazigo underscored the activities of the Programme on which APOC Management will be focusing attention in the coming months. Among these, the management will aim to: strengthen the APOC partnership, develop the human resources of the Programme, support member countries towards strengthening the national health systems, promote integration of other health interventions through CDTI, review the staffing of APOC Management, continue to strengthen the capacity of APOC countries in the management of SAEs, and maintain treatment in conflict areas. She assured JAF that APOC Management rvill work closely with, and consult, the APOC partners as much as necessary and will build a strong spirit of teamwork with her colleagues within APOC Management. 5. Mr Jean-Christophe Deberre, Director, Department of International Policy Development of the Ministry of Foreign Affairs of France, in his formal opening of the session, welcomed participants to the meeting and expressed the pleasure of the Government of France to be hosting a meeting of the onchocerciasis control programmes for a second time in two decades. He thanked the donors for their continued support to onchocerciasis control, particularly Merck and Co. Inc., for the I 2donation of Mectizan free of charge for as long as needed for the treatment of onchocerciasis throughout the world. 6. DrFrdddricGoyet,DirectoroftheHealthBureauoftheMinistryofForeignAffairs,France,was elected to chair JAFI I and Mrs M.J. Mwaffisi, Permanent Secretary of the Ministry of Health of the United Republic of Tanzania was elected as Vice-Chair. 7. The provisional agenda attached as Annex 2 was adopted without modifications. However, the Forum subsequently requested that the agenda of future JAF sessions be reorganized in a manner to allow for more time for discussions. 8. The reflections of the Committee of Sponsoring Agencies (CSA) were presented by Dr James Mwanzia, Chairman of the Committee. In his statement, he underscored the main activity undertaken by the Committee, namely, organizing the External Evaluation of APOC and the Mid- term Review of SIZ and the ex-OCP countries. He informed the Forum that a Vision on the future of APOC had been prepared by CSA and will be presented to JAF for guidance. He also announced that a Donors' Conference was being planned for June 2006 to formalize the way forward in implementing the Vision and to mobilize resources for the financial shortfall to complete APOC. CSA was also proposing to convene a meeting bringing together all 30 onchocerciasis-endemic countries in Africa to discuss the strategy for eliminating onchocerciasis throughout the continent. 9. CSA called for a concrete debate on integration of CDTI and the neglected tropical diseases to take place within the onchocerciasis community at large and especially within the endemic countries. 10. The Forum was informed by the chair of the CSA that a statue was unveiled in October2005 at the Royal Tropical Institute in Amsterdam, the Netherlands, in recognition of the unstinting and steadfast support of the donor community to onchocerciasis control for the past three decades. I l. A video film on onchocerciasis control activities, using Cameroon as an example was projected which further highlighted some of the achievements and operational challenges facing the Programme. Among other issues, the Honourable Minister of Health of Cameroon emphasized the critical role of the community volunteers, the experience in the management of Serious Adverse Events (SAEs) and the importance of sustainability and efficiency of APOC activities. He appealed to donors to continue their support to APOC to enable it achieve its objective. He also welcomed the idea of a proposed Donors'Conference in June 2006. 12. A summary of the discussions of the meeting is presented under the following agenda items. A full report of the meeting will be made available at a later date. PROGRESS REPORT OF THE WORLD HEALTH ORGANIzuTION, REPORT OF THE TECHNICAL CONSULTATIVE COMMITTEE AND OF THE NON-GOVERNMENTAL DEVELOP MENT GROUP FOR O|VC HOCERCIASIS CONTROL 13. JAF congratulated APOC Management, the TCC and the NGDO Group on their achievements over the past year. Having made significant progress in rapid epidemiological mapping of onchocerciasis (REMO) in DRC, Angola and Sudan, it is estimated that 89 million people are ? t I l 5 a3 now at risk of contracting onchocerciasis and 37 million people are infected with the disease. Progress in the implementation of CDTI projects had also allowed for the treatment of over 38 million people through 72 projects under implementation in 2004. 14. To ensure the availability to the public at all times of accurate data on APOC activities, JAF requested that APOC Management should regularly update APOC data (on e.g. treatments, blindness, population at risk) in the Weekly Epidemiological Record of WHO. 15. The Forum also remarked that there was need for a gradual decentralization of APOC activities to participating countries and called on APOC Management to develop a strategy for decentralization of its activities to the countries. The Forum also requested that APOC Management establish working relationship with relevant regional organizations which could play an important role in promoting political and financial commitment of participating countries to onchocerciasis control activities before and during the Phasing out period of APOC and thereafter REPORT OF THE 2OO5 APOC EXTERNAL EVALUATION 16. The report of the 2005 External Evaluation was presented by Drs Eleuther Tarimo and Bernard Philippon. The objective of the evaluation was to assess: l) whether APOC was making progress towards meeting its 2010 objectives; 2) what measures should be taken to fulfill those objectives; and 3) how best CDTI activities can be sustained after 2010 to ensure the elimination of onchocerciasis as a public health problem throughout APOC countries. 17.The evaluation team concluded that, although on the whole, APOC was moving towards the achievements of its objectives, the target of 2010 will not be achieved because of delays, particularly related to conflict situations. Consequently, the evaluation team recommended that in view of the importance of ensuring that all projects are brought to a satisfactory conclusion, the APOC Trust Fund should be extended to support those projects up to 2015 on a decreasing scale. The team also made appropriate recommendations for each of the issues they identified. 18. JAF commended the External Evaluation Team for undertaking this important evaluation. The Forum remarked that the report was received very late by participants who had not had time to review it. JAF therefore noted the report and requested that comments be sent by e-mail to CSA which would in turn: a. reconcile the comments of a[ partners on the evaluation report; b. draw up a plan of action based on the outcomes of the evaluation; c. convene a meeting of partners preferably in an African country in 2006. l9.Nigeria and Cameroon expressed interest in eventually hosting the meeting of partners to be convened by CSA in 2006. REPORT OF THE MID-TERM REVIEW OF SPECIAL INTERVENTION ZONES (SIZ) AND EX- OCP COUNTRIES 20. Although of interest to all partners, it was clarified that it was not the mandate of JAF to review the report of the Mid-term Review. JAF however made the following observations on the presentation of the report: I 'l t 4ll lll IV vl vil There is a need to ensure that the achievements of OCP are sustained; The situation in Sierra Leone requires particular attention and perhaps it would be appropriate to consider including Sierra Leone in APOC; Surveillance is critical to ensuring sustainability of the achievements in ex-OCP countries. The Multi-Disease Surveillance Centre (MDSC) should be given appropriate support to enable it provide effective surveillance to all ex-OCP countries; There is an urgent need for an intercountry mechanism which should liaise closely with APOC in overseeing onchocerciasis control activities in ex-OCP countries and throughout Africa; Advantage should be taken of existing regional organizations to promote policy- related advocacy for onchocerciasis control ; Justification for continuing vector control in the SIZ countries was questioned given the high cost involved. Therefore, although the Mid-term Review team recommended the continuation of vector control activities, it was suggested that further review be conducted to identify ways of making savings that could be used to further strengthen CDTI activities in the SIZ countries; WHO was strongly encouraged to ensure that its own internal administrative rules regarding staff contracts do not jeopardize the successful completion (with appropriately trained staff) of the activities in the SIZ countries. 21. JAF called on WHO and the World Bank to note the observations of JAF and to take appropriate action VISION FOR THE FUTURE OF ONCHOCERCIASIS CONTROL IN AFRICA 22.On the behalf of CSA, Dr. Ousmane Bangoura presented to JAF for guidance a vision paper on the future of APOC. The vision was based on lessons learnt from implementing OCP and APOC, opportunities that CDTI could offer to broaden the scope of the formal health systems to reach, neglected poor populations particularly in remote areas, and ongoing changes in national and international health priorities. The strategic aim of CSA is to advocate for: a. strengthening the implementation of onchocerciasis control activities at country level and for the extension of the duration of APOC beyond 2010, to allow for the full 5 years of financing of CDTI projects whose implementation may have been delayed for various reasons; b. broadening the mandate of APOC to include ex-OCP countries; c. the use of APOC structure as a catalyst for the integration of CDTI with other appropriate health interventions, especially neglected tropical diseases. 23.JAF requested that a reflection paper be developed by CSA and presented to the proposed 2006 meeting of the partners (see also paragraph 18.c). In this regard, the Forum suggested that a o t \ a5 working group, that represents the overall partnership, be set up under the auspices of CSA to reflect on the following points: a. The future of the Programme until 2010 including the modalities of an eventual extension; b. Modalities of continuing control activities in the countries (transfer, integration, funding and advocacy); c. Control of the disease in the whole of Africa: APOC, SIZ areas (after 2007), ex-OCP countries and countries in conflict situation; d. Eventual financing on: i. Current availabilities, ii. Future projections based on forecasted availabilities and anticipated budgets after 201 0. 24. JAF noted with regret the withdrawal of FAO from CSA. It urged CSA to ensure that UNDP resume active participation in the activities of CSA. The Forum recognized that the current legal framework did not allow for a change in the membership of CSA and therefore emphasized the need for a more active participation of the broader APOC partnership in the discussions of CSA as may be appropriate. 25.The Forum acknowledged that the CDTI strategy and structure could be utilized to promote integration of compatible health interventions in the countries thereby pooling synergies and attracting other partnerships. However, countries should take the lead, eventually with the support of APOC, in formulating policies on integration based on their individual needs. It was further emphasized that integration should be at all levels - global, regional, national and community levels. 26. [t was also concluded that APOC is not a vertical programme as it might appear and it was particularly suitable as a catalyst for integration of health interventions within the national health systems. STATEMENTS OF THE PRESIDENTS OF THE "ORGANISATION POUR LA PREVENTION DE LA CECITE" (OPC) AND OF THE "INSTITUT DE RECHERCHE POUR LE DEVELOPMENT" (IRD), FRANCE 27 .ln his address to JAF, Professor Pouliquen, President of the "Organization pour la Prdvention de la C6citd" (Organization for the Prevention of Blindness) recounted the relations of OPC with onchocerciasis control and the role of NGDOs in APOC activities. He thanked Merck and Co. Inc and the Mectizan Donation Program (MDP) for donating ivermectin all these years. He also touched on issues relating to integration, surveillance and motivation of community volunteers as some of the challenges of CDTI. 28. Professor Girard, President of the "lnstitut de Recherche pour le D6veloppement" (Research Institute for Development), outlined the role of IRD in medicine, research and development. He stressed the relationship between prevention and treatment, between health personnel and the communities, and the importance of integration and surveillance. ? 629.The Forum expressed appreciation of the participation of Professors Pouliquen and Girard in the discussions. COUNTRY REPORTS 30. The Forum acknowledged presentations from DRC, Chad, Equatorial Guinea, Malawi, Republic of Congo, Uganda, Sudan, Cameroon, Tanzania, Burundi and Angola on their CDTI project activities. The following issues were common to all or most of the countries: a. NOTFs recognize that more CDDs need to be recruited and trained in order to reduce the workload, and existing CDDs should be regularly retrained to maintain/improve the quality of their work; b. therapeutic coverage varies from one area to another in most countries partly due to the fact that CDTI activities are implemented in phases, especially in projects with hundreds of onchocerciasis-endemic communities or projects in very difficult terrain; governments continue to contribute financially to CDTI activities with increases from the Governments of Burundi, Cameroon, Chad, Congo, Malawi and Uganda since 2003. 31. As recommended by JAFIO, it was reiterated that, in future, countries should present an integrated budget, i.e. should include the contributions from all partners - governments, NGDOs and APOC Trust Fund. 32.The attention of the Forum was once again drawn to "nodding disease" and epilepsy and their possible link with onchocerciasis. JAF requested that TDR should be commissioned to undertake research on "nodding disease". CONSIDERATION OF NATIONAL PLANS AND PROJECT PROPOSALS 33.A total of 119 projects have been approved by APOC Management since 1996. In 2005,2new CDTI projects were approved for funding in addition to 54 ongoing projects which submitted their technical and financial reports to TCC for consideration. An amount of US$3,969,969 had been requested from the APOC budget for 2006 to fund the 56 projects. The Forum ratified the requested amount to fund the 56 projects within the overall proposed 2006 budget. OPERATIONAL RESEARCH AND MACROFIL 34. The Forum was updated on the feasibility study of interruption of transmission with ivermectin and rapid epidemiological assessment procedure of Loa /oa (RAPLOA). 35. The firstresults of the multi-country study on Community-directed interventions (CDI) were also presented to JAF which acknowledged the relevance of the study for ongoing discussions on integration. The Forum was pleased to note that TDR had received a grant of $2.4 million from the Bill & Melinda Gates Foundation to complete the study. a c e a7 36. The Forum emphasized the need for a safe and effective macrofilaricide for the control of onchocerciasis. 37. The APOC External Evaluation Team raised concerns, which were echoed by JAF, on the return on investment made on macrofilaricidal drug research and recommended that Macrofil activities should be evaluated to assess its processes, prospects of a macrofilaricide and its cost- effectiveness. 38. An update on Macrofil activities was presented to the Forum which explained the drug development process. It was noted that the Phase II clinical trials of moxidectin will be initiated in the first quarter of 2006 now that the potential safety concerns with one of the veterinarian products containing moxidectin had been resolved. 39. It was explained that, from the point of view of pharmacokinetic reactions, there were no concerns regarding the safety of combining ivermectin, praziquantel and albendezole treatments. It was howev'er cautioned that co-administration of the 3 drugs for the first time in previously untreated populations should be done only with good monitoring and supervision due to potentially high parasite burdens in those populations. SUSTAINABILITY OF CDTI PROJECTS 40. To ensure sustainability, it was stressed that governments should provide sustainable financing for CDTI activities through PRSPs, HIPC funds and other financing options. 41. JAF stressed that APOC Management should intensify advocacy to ensure that governments release adequate funds for, and communities contribute towards, critical CDTI activities that drive sustainability. 42.The need to have a health finance specialist (perhaps seconded from the World Bank) to assist APOC Management address the issues of governments'financing schemes was emphasized. 43. JAF recognized that community ownership and mobilization were also critical for sustainability and that sustainability depended to a large extent on integration of CDTI into the national health system. For example, the Forum noted with pleasure that some CDTI projects in Uganda did not receive any external funding and were reported to be performing well. REPORT ON COST PER TREATMENT WITH IVERMECTIN 44.The results of the cost study presented to JAF showed that the cost per treatment with ivermectin was $0.58. JAF welcomed the study which it felt could be a useful tool for budgeting purposes and for discussions with donors. The Forum also expressed the need for the cost per treatment to be calculated separately for projects in conflict zones. ADDITIONAL HEALTH INTERVENTIONS USING CDTI AS A VEHICLE 45. The Forum requested that APOC Management and countries should share experience on best practices in integration and the use of CDTI as a vehicle for delivering other health interventions a 8to communities. Although this concept was favourable to the Forum, there were concerns as to the financing of these additional interventions. 46. The NGDO Group and Merck & Co. Inc. expressed strong reservations on the use of the ivermectin delivery channel to promote reproductive health related activities. 47 . The Forum requested that APOC Management should encourage and continue to support countries to define national policies on integration and develop strategies for integrating compatible programmes. 48. The Forum was concerned that other health programmes were providing financial incentives to CDDs which could jeopardize the CDTI concept. JAF therefore urged participating countries to define national strategies addressing issues relating to mobilization of, and incentives for, community volunteers. INDEPENDENT MONITORING OF CDTI PROJECTS IMPLEMENTATION 49. The Forum was informed that a tool has been developed by APOC Management that enables projects to independently monitor their CDTI activities (e.g. therapeutic coverage, decision- making process, incentives, CDD motivation, ivermectin availability & supply). The tool has been field tested in Liberia, Cameroon and Nigeria and NOTFs and projects were being encouraged to utilize it for better planning and management of their CDTI activities. PHASE II OF THE LONG-TERM IMPACT ASSESSMENT OF APOC OPERATIONS 50. JAF received with pleasure the partial results of the impact assessment and noted that APOC operations were having significant positive impact on the health of the poor populations. The Forum however remarked that there might be need to undertake a separate study to assess the economic impact of APOC operations. 51. The Forum requested APOC to sharpen its focus on results and the impact on the populations concerned, and consequently to further strengthen surveillance, monitoring and evaluation activities. The Forum also requested APOC Management to conduct periodic beneficiary assessments in a sample of projects which would provide timely information on results. JAF encouraged APOC Management and countries to include in their reporting of APOC activities impact indicators. AUDIT REPORT 52. The Forum noted the report of the External Auditor confirming the correctness of the accounts, receipts and expenditures, which had been submitted for his scrutiny. PLAN OF ACTIOI{ AND BUDGET FOR 2006 53. After a few questions for clarification on the basis of allocation of APOC funds to countries and on the delays for release of funds to some CDTI projects, the Forum approved the Plan of Action for 2006 of APOC and the corresponding budget in the amount of US$ 11,249,000. O o o9 FINANCING OF THE AFRICAN PROGRAMME FOR ONCHOCERCIASIS CONTROL (APOC) 54. The Forum noted that governments of l1 APOC countries contributed a total of US$5,253,000 towards onchocerciasis control activities in 2004. These contributions varied from country to country and were mostly in the form of staff salaries, cost of training, supervision and monitoring of CDTI activities. 55. JAF was informed that NGDOs will contribute about $4.6 million towards supporting CDTI projects in 2006. Although some donors have significantly increased their contributions to APOC, it was reported that there is still a forecasted funding gap of $9 million in the APOC Trust Fund. 56. The Forum acknowledged with pleasure the financial pledges made by donors who were present at the meeting. It also reiterated its gratitude to Merck & Co. Inc. which has donated over I billion ivermectin tablets worth more than $1.5 billion over the past l5 years. 57. JAF expressed concern on the repeated absence of some donors at APOC meetings and requested that the World Bank as the fiscal agency should continue its efforts to rekindle the interest of all existing donors in APOC meetings, Donor Conferences and Programme operations and aim to attract new donors. INFORMATION ON THE ACTIVITIES IN THE SPECIAL INTERVENTION ZONES OF THE EX- OCP ET NON-SIZ 58. The Forum received an update of the main activities undertaken in the Special Intervention Zones of ex-OCP countries during the year in the areas of programme management, CDTI, vector control, epidemiological evaluation, preparation of a strategic document, a joint partners' mission to Sierra Leone, a workshop on onchocerciasis control in Sierra Leone; and the organization of the Mid-term Review of SIZ. 59. CDTI activities needed to be reinforced in Ghana and in Sierra Leone; and it was necessary to improve therapeutic and geographical coverage in Ghana. Epidemiological data had improved in most cases in Benin and Togo even if there was still need to reinforce control efforts and strengthen the monitoring system. 60. The main challenges were to maintain support to Sierra Leone during post SIZ period for at least ten years; maintain or further improve the coverage of ivermectin distribution in alI areas until 2012:. maintain vector control at a high level of efficacy; ensure sustainable support to onchocerciasis control and surveillance after SIZ activities end; mobilize funds for increased technical and financial support to field activities and maintain all technical staff up to the end of SIZ activities in 2007. DATE AND PLACE OF JAFL2 6l.At the invitation of the Government of the United Republic of Tanzania, the twelfth session of JAF will be held inTanzania. The date and place will be communicated to participants at a later date. a 10 APPROVAL OF THE CONCLUSIONS AND DECISIONS AND ADOPTION OF THE FINAL COMMUNIQUE 62. The Forum did not adopt the final communiqud which had been distributed before the end of the meeting and some of the recommendations had not yet been included in the final draft. It was therefore agreed that a complete draft be circulated by e-mail to participants for comments. C LOSURE O F THE,SE,SSION 63. After thanking OPC and the Health Bureau of the French Ministry of Foreign Affairs, for successfully organizing the meeting, the Chair of JAF expressed his gratitude to all participants for their active participation in the deliberations and declared closed the l lth session of the Joint Action Forum. a a l1 African Programme for Onchocerciasis Control (APOC) Programme africain de lutte contre l'onchocercose JAF.FAC Annex 1 o JOINT ACTION FORUM Office of the Chairman JOINT ACTION FORUM Onzidme session Paris (France.). 6-9 ddcembre 2005 Ansola FORUM D'ACTION COMMLINE Bureau du Pr6sident ORIGINAL :FRANCAIS Ddcembre 2005 2 3 LISTE DES PARTICIPANTS/LIST OF PARTICIPANTS PAYS/COUNTRIES Dr Jos6 DIAS VAN-DUNEM Vice Ministre, rua 17 de Setembro no l, Ministdre de la Santd, C.P. 1201, Luanda, Angola Tel : 244 2 37 26 90 - Fax :244 2 338249 - E-mail : gvm2@netangola.com Dr Antonio PEDRO Coordonnateur National du Programme National de Lutte contre l'Onchocercose, Luanda, Angola. Tel : 0044 222 39 61 22 - Fax : 0044 222 39 67 22 - E-mail : oncocercose(@snet.co.ao Burundi Dr Libdre NDAYISENGA Coordonnateur National du GTNO, B.P. 1820, Bujumbur4 Burundi, Tel : (257) 24 9333 - F ax : (257 ) 22 9 196 - E-mail : ndal ibere@-yahoo.com Cameroun M. Urbain OLANGUENA AWONO Ministre de la Sante publique, Ministdre de la Santd publique, B.P. 155, Yaound6, Cameroun Tel: (237)2220172 - Fax : (237)2220233 Professeur Assumpta Frangoise Lucienne BELLA Directeur de la Lutte contre [a Maladie, Prdsident du GTNO, Ministdre de la Santd publique, Yaoundd Tel : (237) 996 52 86 - Cellulaire : (237) 223 93 48 - Fax : (237) 222 44 l9 - E-mail : neonbidjoe@yahoo.fr Dr Joseph KAMGNO Conseiller Technique, Loase Cameroun, Ministdre de la Santd, B.P. 1274, Y aoundd, Cameroun Tel : (237) 178 97 36 - Fax : (231) 223 15 64 - E-mail :kamgno@pasteur-yaounde.org 4 5 o 6. I 78. 9 t2 Dr Marcelline NTEP Coordonnateur National du Programme National de Lutte contre l'Onchocercose, Ministdre de la Santd publique, Tel : (237) 222 69 10 - Fax : (231) 222 69 l0 - E-mail : sgoa@camnet.cm Mme Suzanne EBELLE Charg6e de mission, Services du Premier Ministdre, Yaound6, Cameroun, Tel : (237) 768 60 l9 - Fax (237)223 78 80 - E-mail : suzanneebelle@yahoo.fr Conso Brazzaville Dr Damase BODZONGO Directeur Gdndral de la Sant6, Pr6sident du GTNO, Direction Gdndrale de la Sant6, B.P. 2101, Brazzaville, Rdpublique du Congo Tel : Dom (254) 81 57 46 Mobil e Qa\ fi6 42 77 - F ax : (242) 8 I 04 8l - E-mail : bozongo- daniase@yahoo.fr 10 Dr Charlotte GOKABA OKEMBA Directrice de la Lutte contre la Maladie, Premier Vice-Prdsident du GTNO, Direction de la Lutte contre la Maladie, B.P.236,Brazzavllle, Congo, Tel : (242) 551 52 08 - Fax : (242) 81 04 8l - E-mail : charokaka@yahoo.fi 1l Dr Frangois MISSAMOU Coordonnateur National du PNLO, Secr6taire Ex6cutif du GTNO, Direction de la lutte contre la Maladie, 8.P.236 ou 1066, Brazzaville, Congo, Tel: (242) 668 05 63 - Fax : (242) 81 04 8l - E-mail : opc_congo@yahoo.fr t2 Dr Roland zuZET Repr6sentant de l'OPC au Congo, Troisidme Vice-Prdsident du GTNO, B.P. l3089,Brazzaville, Tel:(242) 551 58 49,(242)660 6808-Fax:(242) 81 5895,004724139544- E-mail : rolandrizet@yahoo.fr Guin6e Equatoriale/Equatorial Guinea 13. Dr Nve Justino OBAMA Ministre de la Sant6 et du Bien Etre Social, Ministdre de la Sante et du Bien Etre Social. Malabo, Guin6e Equatoriale, Tel : (240) 27 38 15 - E-mail : justino@intnet 14. Dr Nsue Anacleto SIMA Directeur National, Programme de lutte contre 1'Onchocercose et autres Filarioses, Ministdre de la Sante et du Bien Etre Social, Programme Onchocercose et Autres Filarioses, Malabo, Guinde Equatoriale, Tel (240) 23 26 20 -Fax : (240) 09 32 36 Kenya t5 Dr. David SANG National Coordinator, Division of Vector Borne Diseases, P.O. Box 20750, Nairobi, Kenya Tel 7228191 65 - E-mail: sangdvbd@yahoo.com Malawi 16. Mr Charles Thomson MCHACHA Deputy Minister of Health, Ministry of Health. P.O. Box 30377, Lilongwe 3, Malawi Tel: (265) 01 18 94 00/Cellular phone: 265 095 12 63 - Fax: (265) 01788262 a |l t7 a l8 13 Dr Storn Binton KABULUZI Deputy Director of Preventive Health Services, Ministry of Health P.O. Box 30377 , Lilongwe 3, Malawi, Tel: (265) 1 789 424 - Fax: (265) 1 789 424- E-mail: skabuluzi@yahoo.com Mr Laston SITIMA National Onchocerciasis Coordinator, Ministry of Health, P.O. Box 30377, Lilongwe 3, Malawi Tel: (265) 8 30 34 46 or (265) 1 750 896 - Fax: (265) I 750 896 - E-mail: oncho@malawi.net; lastonsitima@yahoo.co. uk l9 Mr Mac Jay SALIjENI Member of Parliament (MP), P.O. Box 3, Thekerani,Thyolo, Malawi Tel: (265) 8 396751 Nigdria,rNigeria 20 Dr Jonathan Yisa JIYA National Program Director, FederalMinistry of Health, NOCP Secretariat, Abuja, Nigeria, Tel : (Mobile) (234) 8034030212,234 8044184777, Tel/Fax : (Direct number) (234) 9 523 70 49 - Email : jiyajy@yalroo.com: nocpnigeria@yahoo.com - Fax (234) 952 370 49 - Tdl : (234) 952 370 49, E-mai1 : iivaiy@yahoo.com 2t Ms Immaculata THOMPSON Personal Assistant to the Honourable Minister for Health, Abuja, Nigeria, Federal Secretariat Phase 3 Abuja, Nigeria Tel: (234) 09 523 20 48 - Fax: (234) 09 523 70 - E-mail:immaculatanseobot@yahoo.com R6publique d6mocratique du Congo/Democratic Reoublic of Congo 22. Dr Emile BONGELI YEIKOLO YA ATO Ministre de la Sant6, BP 3088,4310, Boulevard du 30 juin, Kinshasa/Gombe, Rdpublique ddmocratique du Congo, Tel : (243) 9989990551810825155 - Fax : Q3$ 998 99 9055 - E-mail : bongel ien@yahoo.fi 23 Dr Kupa Marcel MUKENGESHAYI Coordonnateur National, Programme National de lutte contre l'Onchocercose, Avenue de la Justice No 36, Commune de la Gombe, RDC, Tel : (243) 9999 47 138 - E-mail : mLrkkupa@yahoo.fi; pnlo_rdc@yahoo.fr 24. Mme Awezai B6atrice AMISSI Chargde du partenariat, Ministdre de la Santd, 4310, Bottlevard du 30 juin, Kinshasa/Gombe Tel : (242) 9999 29 9083 - E-mail: beamissi@yahoo.fr Soudan/Sudan 25. Dr Theophillus Ochang LOTTI Minister of Health, Government of South Sudan, Ministry of Health, Sudan Tel: (249) 81 l8 20678 - E-mail: nangechak@yahoo.com 26. Dr Chor Malek TONG National Coordinator, Federal Ministry of Health, National Onchocerciasis Control Programme (NOCP), Khartoum, Sudan, Tel: (249) 912 143820 - Fax: (249) 18378 55 38 - E-mai I : ton g-schewitaak@hotmai l.com or sudanoncho@hotmail.com o 14 21 Dr Samson Paul BABA Director for Preventive and Promotive Services, South Sudan Onchocerciasis Control Coordinator SSOTF, P.O. Box l0l 14-00100 GPO Nairobi, Kenya, Tel: (254) 722 364982 - Cellular phone: (254) 733 600 647 (Roaming) E-mail: samson_baba@yahoo.co.uk; samsonbaba@splmsoh.ors Tanzaniefianzania Mrs Mariam Joy MWAFFISI Permanent Secretary, Ministry of Health, P.O. Box Box 9083, Dar-es-Salaam,Tanzania Tel: (255) 22211 3077 - Fax: (255) 222130009 - E-mail: mjmwaffisi@yahoo.co.uk 29 Dr Raphael B.M. KALINGA Ag. Director Preventive Services, Chair of NOTF, Ministry of Health, P.O. Box 9083, Dar-es-Salaam, Tanzania, Tel: (255) 22211307712122 40617 - Fax: (255)222130009 - E-mai I :rkal i n ga2000@y ahoo. com 30 Dr Grace SAGUTI National Coordinator, Eye Care and Onchocerciasis Control, P.O. Box 9083, Dar-es-Salaam, Tanzania, Tel: (255) 222130009 - Fax: (255)222130009 - E-mail: gracejengo@yahoo.co.uk or nec_ocp@yahoo.com Tchad/Chad 31. M. Naoundangar DJEDOSSOUM Secr6taire G6ndral Adjoint, Ministdre de la Sant6 publique, 8.P.440, N'Djamdna, Tchad Tdl : (235) 51 40 64 ou 28 99 20 -Fax : (235) 52 48 38 - E-mail : 32 M. Nadjilar LOKEMLA Coordonnateur du Programme National de Lutte contre l'Onchocercose, B.P. 4057, N'Djam6na, Tchad, Tellfax: (235) 52 48 38 - E-mail :nadjilar@yahoo.fr Ousanda/Usanda 33. Dr. Richard NDYOMUGYENYI National Onchocerciasis Coordinator, P.O. Box 1661, Kampala, Uganda, Tel: (256) 41 348332-Fax (256) 41 348332 - E-mail: notf@imul.com; notf@vcdmdi.go.ug DONORS/DONATEURS Banq ue A fricaine de Dd ve loppement/African Development B ank 34 Dr Mohamed Mohsen CHAKROLTN Analyste Sup6rieur en Sant6, B.P. 323, 1002 Tunis-Belvedere, Tunisie, Tel : (216) 7l l0 25 I I - Fax (216) 71 33 36 48 - E-mail : m.chakroun@afdb.ors Banque Mondiale/The World Bank 35. M. Alexandre V. ABRANTES Sector Manager, AFTH2, The World Bank, 1818 H Street, NW, Washington DC 20043,Td|: (202) 473 0056 - Fax: (202) 473 8216 - E-mail: Aabrantes@worldbank.org a a 28 t al5 36. Dr Ousmane BANGOURA Onchocerciasis Unit Coordinator, The World Bank,1818 H Street, NW, Washington D.C 20043,Te| (202) 373 4004 - Fax: (202)373 8216 - E-mail: Obangoura@worldbank.org 31. Dr Bernhard LIESE Public Health Specialist (Consultant), Onchocerciasis Coordination Unit, The World Bank,l818 H Street, NW, Washington DC 20433,T61: (202) 458 4491- Fax: (202) 473 8216 - E-mail:_Bliese@worldbank.org 38 Ms Tshiya SUBAYI-CUPPEN Operations Officer, Onchocerciasis Coordination Unit, The World Bank,l818 H Street, NW, Washington DC 20043 Tdl: (202) 413 4511- Fax: (202) 473 8216 - E-mail: Tsuba-vi@worldbank.org Beleique 39. Dr Jacques Walter LARUELLE Charg6 de Programmes, Ministdre des Affaires dtrangdres, Direction gdn6rale de la Coopdration au D6veloppement, rue Brederode 6 - B-1000 Bruxelles, Belgique Tel : (0032) 2 519 07 52 -Fax: (0032) 2 519 05 70 - E-mail : iacques.larueile@diplobel.f'ed.be Canada 40. Mme Catherine BERARD Agent principalde ddveloppement, Agence canadienne de Ddveloppement International,200, promenade du portage, Gatineau (Qu6bec), Canada KlA, 0G4 Tel : (819) 994 4194 - Fax : (819) 997 5453 - E-mail : catherine_berard@acdi-cida.gc.ca France 41. Dr Jean Christophe DEBERRE, Directeur, Ddpaftement du Ddveloppement de la Politique Internationale, Ministdre des Affaires dtrangdres, 20, rue Monsieur, 75007 Paris 07 SP, France Tdl : (331) 53 69 3l 87 - Fax : (331) 45 5l 60 12 42 Dr Frdddric GOYET Chef du Bureau de la Sant6, Ministdre des Affaires 6trangdres, 20, rte Monsieur, 75007 Paris 07 SP, France T6f :015 369 3186 -Fax: 33 015 369 3719 -E-mail : frederic.goyet@diplomatie.gouv.fr 43 M. Hervd D'ORIANO Bureau de la Sant6,Politique hospitalidre, Ministdre des Affaires 6trangdres, 20,rue Monsieur, 75007 Paris 07 SP, France, T6l : 33 015 369 4333 - Fax : 33 015 369 3719 - E-mail : herve. doriano@diplomatie. gouv. fr 44. M. Antonio ORTIZ s/c Ministdre des Affaires dtrangdres, 20,rue Monsieur, 75007 Paris 07 SP, France, Tdl : (331) 53 69 31 87 - Fax : (331) 4s sl 60 l2 45 Mme Sandrine BOUCHER s/c , Ministdre des Affaires dtrangdres, 20, rue Monsieur, 75007 Paris 07 SP, France, Tdl : (331) 53 69 3l 87 - Fax : (331) 45 5l 60 12 M. Philippe ETIENNE s/c , Ministdre des Affaires dtrangdres, 20, rue Monsieur, 75001 Paris 07 SP, France, Tdl : (331) 53 69 31 87 - Fax : (331) 45 51 60 12 ) 46 l6 47. Mme France AGID s/c , Ministdre des Affaires dtrangdres,20, rue Monsieur, 15007 Paris 07 SP, France, Tdl : (331) 53 69 31 87 - Fax: (331)4s 51 60 12 48. Dr Christian BAILLY Expert, Coordonnateur CIRE, Cellule Inter-rdgionale d'Epid6miologie Ouest, Ministdre des Affaires dtrangdres, 20, rue d'Isly, CS 84224,35042 Renne Cedex, France Tel :(332) 99 3529 60 - Fax : (331) 99 3529 6l -E-mail :christian.bailly@sante.gouv.fr Kowait/Kuweit 49. Dr A.M. BAHMAN Agricultural Advisor, P.O. Box 2921Safat,13030 Kuwait, Tel: (965)299918617 - Fax: (965) 299919011 - E-mail: bahman@kuwait-fund.org 50 Mr Qais A.M.S. AL JOAN TechnicalAdvisor, P.O. Box 2921Safat,13030 Kuwait, Tel: (965)2999161 - Fax: (965) 299919011 - E-mail: qais@kLrwait-fund.ore Luxembourg/Luxemburg 51. M. Robert HEMMER Chef du Service National des Maladies Infectieuses, Centre Hospitalier du Luxembourg, 4, Rue Barble, L- 1210, Luxembourg, Tel: (352) 4411 3091- Fax : (352) 4412 79 - hemmer.robert@chl.lu Pologne/Poland 52. Mme Weglenska MAGDALENA Stagiaire d I'Ambassade de Pologne d Paris, l-3 rue de Talleyrand, Paris 75007, Tel: (331) 43 17 34 04 - E-mail : we gle@porzte.wp. pl or piotv. siwicki @ambassade.pol ogne. org.net Arabie Saoudite/Saudi Arabia 53. Mr Hasan ALATTAS Director General, Technical Department, The Saudi Fund for Development, P.O. Box 1887, Riyadh 11441, SaudiArabia Tel: +9661 4641928 - Fax: +9661464 7450- E-mail:hattas@email.com 54 Mr Saud-ALFANTOUKH Director General, Control & Audit Department, The Saudi Fund for Development , Kingdom of Saudi Arabia, P.O. Box 50483, Riyadh 11523, Saudi Arabia Tel: +9661 46 40 723 - Fax: +9661 46 47 450 - E-mail: salfantoukh@yahoo.com Ro),aume-Uni fu nited Kingdom 55. Ms Josephine ASIEDU Deputy Policy Analyst, GlobalHealth Partnerships Team, Policy Division, Department of lnternational Development (DFID), 1 Palace Street, SWIE 5HE, London, England, United Kingdom, Tel. :0207 023 089 1, E-mai I : j-asiedu@dfi d. gov.uk 56. Prof. David MOLYNEUX Director Lymphatic Filariasis Support Centre, Liverpool School of Tropical Medicine, Pembroke Place Liverpool L3 5QA, UK, Tel: (44) 151 705 3291 - Fax: (44) 1 51 709 0354 - E-mail : david. molyneux@liv.ac.uk t a ot7 ONGD/NGDO Christoffel Bl indenmission (CBM) 57 Dr Adrian Dennis HOPKINS Medical Advisor, Regional Office, P. O. Box 58004-00200, Nairobi, Kenya T6l: +254 3751 6541798 - Fax: 254 20 374 0305- - E-mail: ahopkins@cbrni-nbo.org; adrianhopkins@aol.com 58. Mr Fasil Chane BIZUNEH NGDO CDTI Coordinator, P.O. Box 58004-00200, Nairobi, Kenya, Tel: (254) 722 52 7953 - Fax: (254) 20 374 0305 - E-mail: fbchane@yahoo.com The Cafter Center Dr Moses N. KATABARWA Epidemiologist, River Blindness, Lymphatic Filariasis & Schistosomiasis Program, 453 Freedom Parkway, One Copenhill, Atlanta, GA 30307 USA, Tel :770 488 4511 -Fax:770 488 4521 - E-mail : mkataba@emor.v.edu; rzks@cdc.gov 60. Mrs Nicole KRUSE Chief Development Officer, The Carter Center, One Copenhill, Atlanta, GA 30307, USA Tel: (404) 420 5132 - Fax: (404) 688 1701 - E-mail: nkruse@emory.edu 6t Dr Frank RICHARDS Technical Director - River Blindness, Lymphatic Filariasis & Schistosomiasis Program, 453 Freedom Parkway, One Copenhill, Atlanta, GA 30307 USA, Tel: 770 488 4511 - Fax: 770 488 4521- E-mail: fxrl @cdc.eov, frichards@cdc.gov Helen Keller lnternational (HKl) Ms Nancy J. HASELOW Director of Onchocerciasis Programs, HKI Regional Office for Africa, 1l Nord Foire, Azur-Dakar, P.O Box 29898, Dakar-Yoff, Senegal, Tel: (221) 820 74 77 -Fax: (221) 869 l0 63164168- E-mail: nhaselow@hki.org Mrs Alix DE NICOLAY Director of Development, Helen Keller International, Paris, France , Tel/Fax: (331) 47 64 l1 30 - E- mail: adenicolay@hki.org Interchurch Medical Assistance (lMA) 64. Mr Paul DERSTNE President, Interchurch Medical Assistance (IMA), 500 Main Street, Old Main Building, P.O. Box 429, New Windsor, Maryland 21776, USA, Tel: +l 410 635 8720 - Fax: + I 410 635 8726 - E-mail : paulderstine@ interchLrrch. org Lisht for the World 65. Ms. Agnes HAUSER A-1120 Wien, Darnautgasse 13/5, Vienna, Austria, Tel: +43 1 810 l3 00-16 - Fax: +43 1 810 13 00-15 - E-mail: a.hauser@light-for-the-world.org 59 62 63 3 18 Lions Club International Foundation 66. Mme Dominique COSTE Pr6sidente Commission Sight First Afrique Centrale & Ocdan Indien, Reprdsentante de la LCIF pour les Programmes de Sant6, B.P. 4794, Yaoundd, Cameroun, Tel : (237) 220 50 07 - Fax: (237)221 55 67 -E-marl: sight-first@camnet.cm Merck & Co. Inc. Mr Ken GUSTAVSEN Manager, Global Product Donations, Merck & Co., Inc., Whitehouse Station, NJ 08889, United States of America, Tel: (+1)908 423 3088 -Fax:(+l) 9084231987 - E-mai I : ken qustavsen(r?merck.com Mectizan Donation Program Dr Bjorn THYLEFORS Director, Mectizan Donation Program, 750 Commerce Drive, Decatur, 30030 GA, United States of America, Tel:+ 14043711460- Fax: *l 404371 1138- E-mail: bth),lefbrs@taskforce.org Dr Mary ALLEMAN Associate Director, Mectizan Donation Program, 750 Commerce Drive, Suite 400, Decatur, GA, 30030, United States of America, Tel: + I 404 371 1460 - Fax: +l 404 371 1138- E-mai I : mal lernan@taskfbrce.org The Micronutrient Initiative Dr Julia MOORMAN 95, Oxford Road, Rosebank, Johannesburg 20946, South Africa, P.O. Box 2927,Houghton, 2041, South Africa, Tel:27 ll 327 6292-Fax:27 11 327 6286- E-mail: irnoorman@micronutrient.org.za 7t Professor Claire SITA The Micronutrient Initiative Coordinator, A 97 Q Longo, Cit6 Kauka C de Kalamu, Kinshasa, Democratic Republic of Congo, c/o Dr Julia Moorman Tel: (243) 8l 50 49 800 - E-mail: csita@ic.cd Mitosath 72. Mrs Francisca OLAMIJU Executive Director, 605 Hospital Place, Opposite Green Valley, Suites, GRA, Jos Plateau State, Nigeria, Tel: (234) 013 464794 - Fax: (234) 464792 - E-mail: olamijufo@mitosath.ors or mitosath@hotmail.com IJ Prof. Yves POULIQUEN Prdsident, Organisation pour la Prdvention de la Cdcitd (OPC), 17, Villa d'Aldsia, 75014 Paris, France, T6l : (331) 44 12 41 90197 - Fax : (331) 441223 01 74. Dr Andr6-Dominique NEGREL Directeur Ex6cutif, Organisation pour la Prdvention de la C6cit6 (OPC), 17, Villa d'Al6sia. 75014 Paris, France Tdl : (331)44 12 41 93 - Fax : (331) 44 12 23 0l - E-mail : d.nesrel@opc.asso.fr I 6'7 68 69 70 a Oreanisation pour la Prdvention de la Cdcite (OPC) t19 75 Dr Jean Frangois CECCON Directeur des Programmes, Organisation pour la Prdvention de la Cdcitd (OPC), 17, Villa d'Al6sia, 75014 Paris, France T6l (33 1) 44 12 41 90197 - Fax : (331) 44 12 23 0l - E-mail : jf.ceccon@opc.asso.fr Dr Seydou MARIKO Coordonnateur pour la Pr6vention de la Cdcit6 pour I'Afrique de l'Ouest, Organisation pour la Prdvention de la Cdcit6 (OPC), OPC/BRAO,B.P. 1764, Bamako, Mali T6l : (223) 229 63 39 -E-mail : opconcho@afribone.net.ml 77 Dr Philippe GAXOTTE Administrateur et Conseiller de l'onchocercose, Organisation pour la Pr6vention de la C6citd (OPC), 27, rue Vaneau, 75007 Paris, France T6l : (331) 47 05 17 64 - E-mail : phgaxotte@yahoo.fr 78 Mme Hayet GHALEM-KSOUzu Assistante du Directeur des Programmes, Organisation pour la Prdvention de la C6citd (OPC), 17, Villa d'Aldsia, 75014 Paris, France T6l : (331) 44 12 41 98 - Fax : 44 10 23 01 - E-mail :h.ghalem@opc.asso.fr 79 Mme Dominique BERTRAND Assistante de Direction, Organisation pour la Prdvention de la Cdcitd (OPC), 17, Villa d'Al6sia, 75014 Paris , France T6f : (331) 4412 4t 90191 - Fax : (331) 441223 0l 80 Mme C6lia WARIN Assistante anglophone, Organisation pour la Prdvention de la Cdcitd (OPC), 17 villa d'Aldsia, 75014, Paris, France Tdl :(331) 44124190197 - Fax:(331) 441223 01 -E-mail :c.warin@opc.asso.fr 81 Mme Laura JOUANIN Secr6taire, Organisation pour [a Pr6vention de la C6cit6 (OPC), 17 villa d'Al6sia, 75014, Paris, France, Tdl : (331) 4412 4190197 - Fax : (331) 441223 01 Sight Savers International (SSl) 82. Ms Catherine CROSS Manager, International Programmes, Sight Savers International, Grosvenor Hall, Bolnore Road, Haywards Heath, RHl6 4BX, United Kingdom, Tel: +441444 446600 - Fax: +44 1444 446677 -E- mai I : ccross@si ghtsavers.org 83 Mr Simon BUSH Regional Director, West Africa, Sight Savers International, 58 Patrice Lumumba Road, P.O. Box KIA 18190, Airport, Accra, Ghana, Tel: + 233 217742101784702 - Fax: +233 21714209 - E-mail: sbush@si ghtsavers.ors. gh Dr Johnson NGOROK Deputy Regional Director, East, Central, and Southern Africa, Sight Savers International, P.O. Box 34690,00100 GPO, Nairobi, Kenya, Tel: +254 722 56 78 97 ou 254 20 6069701601204 - Fax: +254 20 609623 - E-mail : i nsorok@si shtsavers.or.ke 76 I 84 20 United Front Aeainst Riverblindness 85. Dr Daniel SHLTNGU Chief Executive Director, l3 Carnation Place Lawrenceville, New Jersey 08648ruSA, United States of America, Tel: (609) 771 3674 or (609) 954 3398 - Fax : (609) 530 1594, E-mai I : dlshungu@aol.com PARTICIPANTS DE DROIT / EX-OFFICIO PARTICIPANTS IRD Professeur Jean-Frangois GIRARD Prdsident, Institut de Recherche pour le Ddveloppement (IRD), 2l3,rueLafayette,750l0 Paris Cedex I 0, France 87. M. Serge CALABRE, Directeur Gdn6ral, Institut de Recherche pour le Ddveloppement (IRD), 273, rue Lafayette,750l0, Paris Cedex 10, France, T6l : (331) 48 03 77 01 - Fax : (331) 40 36 26 24 - E-mail : dg@paris.ird.fr M. Jacques CHARMES Directeur Ddpartement Socidtd et Sant6, Institut de Recherche pour le Ddveloppement (IRD), 273, rue Lafayette,75010, Paris Cedex 10, France, Tdl : (331) 48 03 77 77 - Fax: (331) 40362524 Mme Bernadette MURGUE Charg6e de Mission, Ddpaftement Socidtd et Santd , Institut de Recherche pour le Ddveloppement (fRD), 213, rue Lafayette, 75010, Paris Cedex 10, France Tel :(331) 480377 09-Fax:(31)48 0377 09 -E-mail : murgue@Paris.lRD.FR 90 M. Vincent ROBERT Chargd de mission , Ddpartement Soci6t6s et Santd, Institut de Recherche pour le D6veloppement (lRD), 213 rue Lafayette, 75480 Paris Cedex 10 T6l :(331)4079 35 l3 -E-mai[ :v.robert@mnhn.fr 91 Dr MichelBOUSSINESQ Chercheur, Membre CCT/APOC, Institut de Recherche pour le D6veloppement (IRD/DSS), 213 rue Lafayette, 75480 Paris Cedex 10, France, Tel : (331) 42 49 38 l5 - E-mail : boussinesq@ird.fr Dr Christian LEVEQUE Directeur de Recherche, l, rue de Marnes, 92410, Ville d'Avray, Institut de Recherche pour le Ddveloppement (IRD), Paris Cedex 10, France, Tel : (331) 41 l5 01 40 - cleveque@mnhn.fr; c hr i sti anl eve que2@w anad oo. fr 93 Dr Bernard PHILIPPON Directeur de Recherches Em6rite, Institut de Recherche pour le Ddveloppement (lRD), 213, rue Lafayette, 75010 Paris, Cedex 10, France, Tdl /Fax: (331) 40 449404 - E-mail : abphilippon@yahoo.fr Dr Bernard SURUGUE Directeur de Recherche, 32. avenue Henri Varagnat, 93140 Bondi, Paris, France Tdl : (331) 48 02 59 72 - Fax : (331) 48 02 56 52 - E-mail : Bernard.Surugue@ird.fr a 86 88 89 92 a 94 aa 99 95 2l Dr Frangois SIMONDON Directeur UR, Epiddmiologie et Prdvention : Environnement et efficacit6 des interventions, Institut de Recherche pour le D6veloppement (IRD), Centre de Montpellier,34032, Montpellier Cedex, France, Tdl : (33) 4 61 41 617l - Fax : (33) 4 67 4161 62- E-mail : simondof@mpl.ird.fr 96. Mme FAVIER M. Noelle Directrice de la Communication, Institut de Recherche pour le Ddveloppement (IRD), 213, rue Lafayette, 75010, Paris Cedex 10, France, Tdl :(331) 480377 47 -Fax:(331) 40346913 Tdl : (331) 48 03'17 48 - Fax : (331) 48 03 77 42 -E-matl : president@ird.fi 97 Mlle Sophie NUNZIATI Attachde de Presse, Institut de Recherche pour le Ddveloppement (lRD), 213, rue Lafayette, 75010, Paris Cedex 10, France, T6l : (331) 48 03 15 19 - Fax: (331) 40 36 24 55 - E-mail : presse@paris.ird.fr oMS/SIEGE/GENEVE - WHO/HQ/GENEVA Bureau du Directeur gdn6ral de l'OMS/Office of the Director General 98 Dr Catherine LE GALES-CAMUS Assistant Director-General, Noncommunicable Diseases and Mental Health, WHO/Geneva, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland, Tel: (4122) 791 12999 - E-mail: legalescamusc@rvho.int Dr Lorenzo SAVIOLI Director, Department of Control of Neglected Tropical Diseases, WHO/Geneva, 20 Avenue Appia, CH-l2ll Geneva2T,Switzerland,Tel: (4122)1912664-Fax: (4122)7914869 -E-mail: saviolil@who.int 100. Dr Jan H.F. REMME Coordinator, Science Strategy and Knowledge, Special Programme for Research and Training in Tropical Diseases, WHO/Geneva, 20 Avenue Appia, CH-lzl 1 Geneva 27, Switzerland, Fax : 4122 7914854,Telr : 4122 791 3815, e-mail : remmej@who.int 101. Dr Janis Karlin LAZDINS-HELDS Acting Coordinator, Product Development and Evaluation, Special Programme for Research and Training in Tropical Diseases, Geneva, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland, T6l 4122 791 3818 - Fax : 4122 791 4854 - E-mail : lazdinsj@who.int 102. Dr Annette KUESEL Manager,CPRC, OMS/TDR, WHO, 20 Avenue Appia, 1211 Geneva 27, Suwitzerland T el: (4122) 7 9 1 1 5 41 - Fax: (4122) 7 9 1 47 7 4 - E-mai I : kuesela@who. int Bureau du Conseiller Juridique/Lesal Counsel 103. Mr Gian Luca BURCI Conseiller juridique, Organisation Mondiale de la Sant6,20, Avenue Appia, CH 1211, Gendve 27, Suisse, Tel: (4122)791 4754 - Fax: (4122)791 4158 - E-mail: burcigg@who.int 104. M. Claude Henri VIGNES Bureau du Conseiller Juridique, CH l21l Gendve 27, Suisse, Tel: (4122) 791 2638,- Fax: (4122)791 4158 22 Prevention of Blindness and Deafness / Department of Chronic Diseases and Health Promotion 105. Dr. Serge RESNIKOFF Coordinator, Chronic Diseases Prevention and Management, (CPM), Department of Chronic Diseases and Health Promotion, (CHP), World Health Organization, 20 Avenue Appia, 1277 Geneva27, Switzerland ,Tel: +41-22-791-4124 - FAX: +41-22-791-4771 - E-mail: resnikoffs@who.int 106. Dr Tony UKETY NGDO Coordinator for Onchocerciasis Control, Chronic Diseases Prevention and Management (CPM), Department of Chronic Diseases and Health Promotion, (CHP), World Health Organization, 20 Avenue Appia, 121 I Geneva 27, Switzerland, Tel: +41-22-791-1450 - F ax: +41 -22-7 9 1 -47 7 2 - E-mai I : uketyt@who. int CBF/ACT 101. Mr Brendan DALY Chief Accountant, WHO/CBF/ACT,20 Avenue Appia, CH-1211 Geneva, Switzerland Tel: (+4122) 791 2278 - Fax: (+4122) 791 4164 - E-mail: dalyb@who.int OMS/AFRO -WHO/AFRO 108. DrJamesN. MWANZIA Director, Division of Communicable Diseases, P.O. Box BE773, Belvedere, Harare, Zimbabwe Tel: (263) 4 700 026 - Fax: (263) 4 746127 ou (263) 11 420 588 - E-mail: mwanzial@afro.who.int MDSC 109. Prof. Brehima KOUMARE Directeur a.i. , Centre de Surveillance Pluripathologique (MDSC), 01 B.P. 549 Ouagadougou 01, Burkina Faso, Tel: (226) 50 34 38 I 8 - (226) 50 34 28 75 - E-mail: koumareb@oncho.oms.bf SECRETARIAT OMS/ WHO SECRETARIAT 110. Dr Uche AMAZIGO Directrice du Programme Africain de Lutte contre l'Onchocercose (APOC) 0l B.P. 549, Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 - Fax : (226) 34 28 15 - E-mail : amazigouv@oncho.oms.bf 111. Dr Laurent YAMEOGO Manager du Programme, Coordonnateur du Bureau du Directeur, Programme Africain de Lutte contre l'Onchocercose (APOC) 0l B.P. 549, Ouagadougou 01. Burkina Faso Tel : (226) 34 29 53 - Fax : (226) 34 28 75 - E-mail : yameogol@oncho.oms.bf 112. Dr MounkallaNOMA Chef, Unit6 d'Elimination du Vecteur, Programme Africain de Lutte contre l'Onchocercose (APOC) 0l B.P. 549, Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 - Fax : (226) 34 28 7 5 - E-mail : nomam@oncho.oms.bf O t a23 I 13. M. Honorat ZOURE Responsable charge de la Biostistique, Informatique et Cartographie (BIM), Programme Africain de Lutte contre l'Onchocercose (APOC) 01 B.P. 549, Ouagadougou 01, Burkina Faso Tel : (226) 34 29 53 - Fax : (226) 34 28 75 - E-mail : zoureh@oncho.oms.bf 114. M. K. AGBLEWONU Administrateur du Budget et Finances, Programme Africain de Lutte contre l'Onchocercose (APOC) 01 B. P. 549, Ouagadougou 0 I , Burkina Faso, Tel : (226) 34 29 53 - Fax : (226) 34 28 7 5 - E-mail : agblewonuk@oncho.oms.bf 115. M. Yaovi AHOLOU Charg6 d'Administration, Programme Africain de Lutte contre l'Onchocercose (APOC) 01 B.P. 549, Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 - Fax : (226) 34 28 7 5 - E-mail : aholouy@oncho.oms.bf 116. M. Samuel Bamfo ODAME Traducteur, APOC, Programme Africain de Lutte contre l'Onchocercose (APOC) 0l B.P. 549, Ouagadougou 01, BurkinaFaso, Tel:(226)3429 53 -Fax: (226)342875- E-mail : bamfos@oncho.oms.bf 117. M. Abdoulaye DARIBI APOC/AFRO Liaison Office, World Health Organization, 20 Avenue Appia, l2l1 Geneva27, Switzerland, Tel: (4122) 7913883 - Fax : (4122)791 4190 - E-mail : daribia@who.int 118. Mme Edith OUEDRAOGO Assistante Administrative chargde des Rdunions, Programme Africain de Lutte contre l'Onchocercose (APOC) 0l B.P. 549, Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 - Fax : (226) 34 28 7 5 - E-mail : kaboree@oncho.oms.bf I19. Mme Agnds DRABO Assistante Administrative, Programme Africain de Lutte contre l'Onchocercose (APOC) 0l B.P. 549, Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 - Fax : (226) 34 28 7 5 - E-mail : draboa@oncho.oms.bf TCC 120. Prof Ekanem BRAIDE Vice Chancellor, Cross River University of Technolory, Calabar, Chair of TCC, P.O. Box 3679, Calabar, Nigeria, Tel: (234) 080 33 41 68 42,Fax: (234) 087 230 9141087 230 911, E-mail: ekanem_b@hotmail.com; onchocal@skannet.com; ekanem-b@hotmai l.com 121. Prof Deborah MCFARLAND Associate Professor, Department of Intemational Health, Rollins School of Public Health, Emory University, TCC member, 1518 Clifton Road, Atlanta, Georgia, 30322, Tel: (1) 40472'7 7849 - Fax: (1) 404 727 4590, E-mail: dmcfarl@sph.emory.edut 24 EQUIPE D'EVALUATION EXTERNE D'APOC ET SIZIAPOC AND SIZ EXTERNAL EVALUATION TEAM 122. Dr Eleuther TARIMO APOC Extemal Evaluati on Team Leader, P.O. 8ox 3327 1, Dar-es-Salaam, T anzania Tel: (255) 748 3185741 (255) 222 735051(255) 222 73568- E-mail: Eleuther@Ud.Co.Tz or El euther@Uccmail. Co.Tz 123. Prof. Adenike ABIOSE, SIZ External Evaluation Team Leader, P.O. Box2977l, Secretariat Main Office, Ibadan, Oyo State, Nigeria Tel/Fax: (234)28107434 -E-mail: adenikeabioseo@yahoo.com; abiose@skannet.com; abiose@infoweb. com. ng 124. Dr Andrd YEBAKIMA Evaluateur/CCS, Centre de d6moustication, BP 697 97200, Fort de France (Martinique) T6l : 0596598544 - Fax : 0596702646 -E-mail : yebakima@cg972.fr INTERPRETES/INTERPRETORS 125. M. Christian STENERSEN Interpretor, Les Rossanets, F-01 170 Segny (France) Tel : (334) 5041 7880 126. Mlle Genevidve CLEMENT Interprdte, 80, rue de Meyrin, F-01210 Ferney-Voltaire, France (r6gion de Gendve) Tel : (334) 50 40 76 s0 - 127. Ms Mara SFREDDO Interprdte, 11, Ch. de Ia Rochette,7202, Gendve, Suisse Tel : 4122 740 4851 - E-mail : sfieddo@bluewin.ch 128. Mme Madeleine GIROT Interprdte, 4, rue des Foss6s, Saint Maral, 75005, Paris, France Tel : (331) 43 37 8l 87 - E-mail : mgirot@aiic.net OBSERVATEURS/OBSERVERS Burkina Faso 129. Dr Mdtd BONKOLrNGOU Directeur Rdgional de la Santd des Hauts-Bassins, entomologiste national, Programme de lutte contre I'onchocercose, 0l BP 1508, Bobo-Dioulasso 01, Burkina Faso Tdl:(226)2097 14 21, Mobile 702527 51, E-mail:metew4@yahoo.fr DANIDA 130. Dr Erling M. PEDERSEN Technical Advisor for Danida, DBL-Institute for Health Research and Development, Jaegersborg All6 I D, DK-2920 Charl ottenlund, Denmark Tel: +45 77 32 77 63 (direct)/+4s 77 32 77 32 (switchboard) - Fax: + 45 77 32 77 33 - E-mail: empedersen@dblnet.dk I 3 , 25 Ghana 131. Dr John GYAPONG Director of Research, Programme Manager, LF and Oncho, Health Research Unit, Ghana Health Service, Oncho Control Programme, P.O. Box GP 184, Accra, Ghana Tel:(233)2168 1085-Cel: (233)24265081-Fax: (233)212267 39 -E-mail:John.Gyapong@hru- ghs.org Guinde Conakry 132. Dr Nouhou Konkour6 DIALLO Coordonnateur National du Programme National de lutte contre l'onchocercose et la Cdcitd (PNLO), Ministdre de [a Santd publique, Programme Onchocercose - C6cit6, B.P. 585, Conakry, Rdpublique de Guinde Tdl : (224) 25 3371 - Fax : (224) 433707 - E-mail : dnouhoufr@yahoo.fr Mali l 33. Dr Mamadou TRAORE, Coordonnateur National du Programme de lutte contre 1'onchocercose, Direction nationale de la Santd, Bamako, Mali Tel : (223) 222 64 97 - Fax : (223) 223 36 74 - E-mail: traorernot@yahoo.fr ou motraore@dnsmali.org 134. Dr Moussa SOW, Entomologiste national, Direction nationale de la Sant6, 8.P.233, Bamako, Mali Tel : (223) 222 29 21 - Fax : (223) 223 36 74 - E-mail : msow@dnsmali.org Oreanisation Ouest Africaine de la Santd/West African Health Orsanisation 135. Dr Kabba T. JOINER Director General, West African Health Organisation, 0l B.P. 153, Bobo-Dioulasso, Burkina Faso Tel: (226) 2097 1560 - Fax: (226) 2097 2972 - E-mail: wahooas@fasonet.bf or kabajoiner@hotrnail.com 136. Prof. Kayode ODUSOTE Director, Division of Human Resources Development, West African Health Organization 0l B.P. 153, Bobo-Dioulasso, Burkina Faso, Tel: (226) 2097 0097 -Fax: (226) 2097 5712 - E-mail: wahooas@f-asonet.bf; or kodusote@yahoo.com;kodusote@wahooas.org ' AA/Mtg 19.12.2005 a a 26 Annex 2 AGENDA JAFl1, Paris 6-9 December 2005 l. Opening of the session 2. Election of Officers 3. Adoption of Agenda 4. Reflections of the Committee of Sponsoring Agencies 5. Progress Report of the World Health Organisation 6. Report of the Technical Consultative Committee (TCC) 1. Reporl of the NGDO Coordination Group for Onchocerciasis control, including support of the group to APOC activities 8. APOC External Evaluation Report (2001-2004) 9. Mid-term evaluation report on activities of the Special Intervention Zones (SIZ) and evaluation of the efficacy of the onchocerciasis surveillance systems in the ex-OCP countries 10. Vision for the future of Onchocerciasis Control in Africa I l. lnterventions of the Presidents of the Organizalion for the Prevention of Blindness (OPC) and the Research Institute for Development (lRD), France 12. Country reports: (i) (Congo, Nigeria, Tanzania, Cameroon, Central African Republic, Uganda, Malawi, Sudan, Equatorial Guinea, Democratic Republic of Congo, Liberia, Chad, Ethiopia, Burundi, Angola)(ii) (Gabon, Mozambique, Rwanda, Kenya) l3 14 15 Consideration of National plans and Project proposals Operational research and MACROFIL Community-Directed lnterventions (CDI): conclusions and recommendations of special meetings on CDIs and the integration of community-based programmes Sustainability of CDTI projects(i) Updates on project evaluation(ii) Monitoring the implementation of sustainability plans l 6 17. Report on cost per treatment with ivermectin t I 20. 22. 18. l9 21 23 24. 27 Additional health interventions using CDTI as a vehicle Independent participatory monitoring of CDTI projects Phase II of the long-term impact assessment of APOC operations Audit report Plan of Action and Budget for 2006 Financing of the African Programme for Onchocerciasis Control (APOC) (i) Country contributions(ii) NGDO contributions(iii) Repor-t of the World Bank(iu) Pledging of Donor contributions Information on activities in the Special Intervention Zones (SIZ) of the ex-OCP, non-SIZ areas, and the Multi-Disease Surveillance Centre (MDSC) of Ouagadougou Other matters Date and place of the twelfth session Consolidation of JAFI l conclusions and decisions and drafting of final communiqud Final approval of the conclusions and decisions and adoption of the final communiqud Closure of the eleventh session DrR/APOC/08.1 1.0s 25. 26. 27. 28. 29. a I I t